Second Genome - Wiki

Second Genome is a company that has the mission to redefine disease in terms of microbiome medicine. It uses proprietary microbiome drug discovery and development platform to find effective peptides, proteins and small molecule therapeutics.

Timeline

April 2016

Second Genome raises a $51,000,000 series B round from Digitalis Ventures, LifeForce Capital, Matthew Winkler, Mayo Clinic, Morgenthaler Ventures, Pfizer Venture Investments, Roche Venture Fund, SR One and Seraph Group.

June 5, 2013

Second Genome raises a $11,500,000 series A round from Advanced Technology Ventures and Morgenthaler Ventures.

August 9, 2011

Second Genome raises a $4,999,999 series A round from Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group and Wavepoint Ventures.

Funding Rounds

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

News

Title

Author

Date

Publisher

Description

Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD)

Second Genome

June 22, 2021

www.prnewswire.com:443

/PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight and AI workflows to discover and develop precision...

Second Genome to Present Big Data Analytics Capabilities at the Microbiome Data Congress

Second Genome

June 9, 2021

www.prnewswire.com:443

/PRNewswire/ -- Second Genome, a tech-enabled biotechnology company that extracts microbial genetic insights to make transformational precision therapies and...